Forensic Analysis · Healthcare / Pharmaceuticals / Biotech · as of Jun 27, 2026
BIOCRYST PHARMACEUTICALS INC (BCRX)
A forensic read on BIOCRYST PHARMACEUTICALS INC built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
D · Weak — demands caution
Forensic grade
Distress
Financial health
-2.6
Altman Z-score
Clean
Earnings quality
2
Forensic signals
-328.8%
ROE
$2.5B
Market cap
BIOCRYST PHARMACEUTICALS INC earns a D (Weak — demands caution) forensic quality grade, and its Altman Z-score is -2.6, placing it in the Distress zone. 2 forensic signals were flagged in its latest SEC filings, led by share-count dilution.
What the filings flag
+5.9%/yrShare-count dilution.Diluted share count changed +18% over the last 3 years to FY2025 (+5.9%/yr). The count is GROWING — existing holders are being diluted. That's ~5.9% shaved off per-share growth every year — total profit has to grow that much just to keep earnings-per-share flat, and a stake held since FY2022 has been diluted ~18%.
10% of revStock-based comp load.Stock-based compensation ran 10% of revenue and 25% of free cash flow in FY2025 — about $0.39 per diluted share. Meaningful — reported free cash flow flatters the economics, since SBC is a real cost paid in shares.
Key fundamentals
Net Margin30.2%
Free Cash Flow$344.9M
Latest Revenue$874.8M
Revenue Growth YoY+94.1%
Go deeper — free with an account
The forensic grade and screens above are free — no account needed. An account adds the full interactive deep-dive on BIOCRYST PHARMACEUTICALS INC:
🔒The written investment read — what the numbers mean, in plain English
🔒Ask anything about BCRX's filings — AI Q&A across the 10-K, 10-Qs & 8-Ks
🔒Interactive valuation — reverse-DCF sliders, Monte Carlo & scenario stress
🔒Calibrated 12-month price forecast, with the math shown